Showing results (1151-1160 of 1,290) with videos related to

Sort By:
Pageof 129
ESC Heart Failure|May 19, 2025
Quality of life after transcatheter tricuspid valve repair: results from the Tri.FR trialSabina Istratoaie, Pascal de Groote, Nicole Karam, et al.
Nature|November 15, 2023
The extracellular matrix dictates regional competence for tumour initiationNordin Bansaccal, Pauline Vieugue, Rahul Sarate, et al.
The Lancet Regional Health. Europe|July 29, 2024
Lanreotide versus placebo for tumour reduction in patients with a <sup>68</sup>Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessmentTessel M Boertien, Madeleine L Drent, Jan Booij, et al.
Infection|June 19, 2024
Activation of the MAPK network provides a survival advantage during the course of COVID-19-induced sepsis: a real-world evidence analysis of a multicenter COVID-19 Sepsis CohortAndrea Witowski, Lars Palmowski, Tim Rahmel, et al.
BJUI Compass|April 23, 2026
Clinical trial protocol of PODRACING: A randomized controlled trial evaluating 3D perfusion zone models for selective arterial clamping during robot-assisted partial nephrectomyJoris Vangeneugden, Saar Vermijs, Pieter De Backer, et al.
Lancet (London, England)|March 22, 2015
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosisRodney Dawson, Andreas H Diacon, Daniel Everitt, et al.
Circulation|April 25, 2023
Serum and Pulmonary Expression Profiles of the Activin Signaling System in Pulmonary Arterial HypertensionChristophe Guignabert, Laurent Savale, Athénaïs Boucly, et al.
Cell Reports|April 7, 2016
Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor ImmunityTania Løve Aaes, Agnieszka Kaczmarek, Tinneke Delvaeye, et al.
American Journal of Respiratory and Critical Care Medicine|April 2, 2024
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical TrialKamunkhwala Gausi, Elisa H Ignatius, Veronique De Jager, et al.
Archives of Cardiovascular Diseases|September 2, 2020
Epidemiological characteristics and therapeutic management of patients with chronic heart failure who use smartphones: Potential impact of a dedicated smartphone application (report from the OFICSel study)Théo Pezel, Emmanuelle Berthelot, Jean Gauthier, et al.
Pageof 129